High-Resolution 7T MR Imaging of the Motor Cortex in Amyotrophic Lateral Sclerosis

M. Cosottini, G. Donatelli, M. Costagli, E. Caldarazzo Ienco, D. Frosini, I. Pesaresi, L. Biagi, G. Siciliano and M. Tosetti

AJNR Am J Neuroradiol 2016, 37 (3) 455-461
doi: https://doi.org/10.3174/ajnr.A4562
http://www.ajnr.org/content/37/3/455
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disorder that entails degeneration of both upper and lower motor neurons,1 producing fasciculation, muscle wasting and weakness, increased spasticity, and hyperreflexia. However, the masking effect of the lower motor neuron involvement that reduces muscle strength and reflexes may make it hard to reveal clinical evidence of pyramidal involvement. Electrophysiologic investigations, such as prolongation of central motor conduction time in motor-evoked potentials in transcranial magnetic stimulation, may detect the upper motor neuron involvement, but results are conflicting and these measures are not a sensitive tool or a useful indicator of disease severity or prognosis.2-4 Therefore, a robust in vivo biomarker of UMN impairment, though desirable,5 is not available.

The hallmark of UMN pathology in ALS is depopulation of the Betz cells in the motor cortex and axonal loss within the descend-
ing motor pathway associated with myelin pallor and gliosis of the corticospinal tracts.6

Conversely, also, characteristic of ALS pathology similar to that in other neurodegenerative disorders is the occurrence of a neuroinflammatory reaction, consisting of activated glial cells, mainly microglia and astrocytes, and T-cells.7 In transgenic mouse models of mutant SOD1-associated familial ALS, reactive microglial cells and astrocytes actively contribute to the death of motor neurons.7

Moreover, a significant association between cortical microgliosis and UMN damage has been described by using PET with a radioligand for microglia.8

Recently, an ex vivo study with Perls’ DAB staining detected intracellular and extracellular iron deposits in the motor cortex of patients with ALS. Iron in the form of ferritin is detected in activated microglia (CD68+) in the middle and deep layers of the motor cortex, sparing the superficial layers.9

Gradient recalled-echo T2* sequences, which can provide signal magnitude, phase, and their combination in susceptibility-weighted imaging,10 are considered the most appropriate technique to visualize small amounts of uniformly distributed iron, such as ferritin,11,12 and are the most sensitive sequences for detecting the low signal intensity in the precentral cortex in patients with ALS.13

The introduction of ultra-high field (UHF) MR imaging equipment greatly increases the sensitivity to susceptibility phenomena and allows obtaining in vivo spatial resolution of approximately 200 μm, which enables determination of the cortical layers.14

The aims of our study were to measure the thickness of the primary motor cortex (M1) and to describe the distribution of the iron-related signal changes in the M1 of patients with ALS as a possible in vivo biomarker of UMN impairment by using targeted high-resolution gradient recalled-echo T2* sequences at UHF.

MATERIALS AND METHODS

Patients and Controls
Twenty-two patients (5 women and 17 men; mean age, 61 ± 12 years) with a diagnosis of definite ALS (limb onset) according to the revised El Escorial diagnostic criteria15 were enrolled (On-line Table 1). Patients with dementia were excluded by administering the Mini-Mental State Examination16 and the Frontal Assessment Battery,17 as short and rapid bedside tests for a screening of cognitive, behavioral, and global executive dysfunction. Clinical history and standard neurologic and psychiatric assessment were used to rule out possible neuropsychiatric comorbidities and other neurodegenerative diseases.

Patients underwent CSF and plasma laboratory analysis to respectively assess concentration of β-amyloid, α, and p-τ neuronal proteins and some peripheral oxidative stress biomarkers such as advanced oxidation protein products, ferric-reducing ability of plasma, and thiols.18 Neurophysiologic investigation included motor-evoked potentials with calculations of central conduction time, cortical latency, and cortical silent period. Disease severity was evaluated by using the ALS Functional Rating Scale-Revised (ALSFRS-R) (range, 0–48),19 the Medical Research Council scale for segmentary muscle strength (range, 0–130),20 and a composite semiquantitative arbitrary score of UMN burden (UMN score; range, 0–33) (On-line Table 2).8,21,22 Disease duration was expressed in months from symptom appearance to MR imaging acquisition, while disease progression rate (DPR) was calculated according the following formula: (48 − ALSFRS-R)/Disease Duration.23

Fourteen right-handed healthy subjects (HS), age-matched with patients (8 women and 6 men; mean age, 58 ± 12 years), were enrolled to compare the cerebral motor cortex morphology with respect to patients with ALS. HS were volunteers who had no history of psychiatric and neurologic disorders; their neurologic examination findings were normal.

All patients and controls gave their informed consent to the enrollment and diagnostic procedures on the basis of the adherence to an experimental protocol “Clinical Impact of Ultra-High Field MR Imaging in Neurodegenerative Diseases Diagnos” (RF-2009-1546281) approved and funded by Italian Ministry of Health and cofunded by the Health Service of Tuscany. The study was approved by the local competent ethics committee.

MR Imaging Acquisition

MR imaging experiments were performed on a 7T MR950 scanner (GE Healthcare, Milwaukee, Wisconsin) equipped with a 2CH-TX/32CH-RX head coil (Nova Medical, Wilmington, Massachusetts).

The MR imaging protocol included a high-resolution 2D multiecho gradient-echo sequence with TE = 10 ms and 20 ms, TR = 500 ms, flip angle = 15°, NEX = 2, section thickness = 2 mm, FOV = 112 mm, and in-plane resolution = 250 μm, targeted to the M1, oriented in the axial plane, and covering the cerebrum from the vertex to the internal capsule. The total acquisition time was 7 minutes 32 seconds.

Image Analysis

Visual Inspection and Subjective Assessment. Two expert neuroradiologists (M.Cosottini and I.P.) blinded to the clinical status of subjects visually evaluated, independently, images on the basis of morphologic criteria.

The M1 in the precentral gyrus was identified on UHF MR images for the presence of the “hand knob.”24 The anatomy of the cerebral motor cortex at the level of the M1 was evaluated on the basis of accepted cognition sourcing from anatomic atlases25 and MR imaging studies26,27 and atlas28 at UHF. The normal anatomy of the M1 at UHF MR imaging consists of deeper cortical layers identified as a slight hypointense band immediately subjacent to a thinner superficial hyperintense layer. The subcortical hypointense line corresponding to U-fibers appears smooth, and the gray-white junction, poorly demarcated (Fig 1A, -B).

When the M1 anatomy differed from such configurations, and namely the M1 deeper layers were particularly thin,23,29 and/or hypointense9,30 (Fig 1D, -E), images were judged as belonging to patients with ALS.

Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy in distinguishing patients and HS were calculated for each reader. Interobserver agreement was calculated with the Cohen κ statistic.
Differences in UMN scores between correctly diagnosed and misdiagnosed patients were evaluated by a Mann-Whitney U test.

Quantitative Assessment. For each cerebral hemisphere, thickness and signal intensity of the deeper layers of M1 were measured in 4 anatomic regions corresponding to the Penfield’s areas of foot, leg, hand, and face (Fig 1C-F). Signal intensities were measured by using oval ROIs of 4 mm² and were normalized with respect to those of the superficial cerebral cortex of the left precuneus. Measurement of cortical thickness was obtained by tracing, with an electronic caliper, a line encompassing the deep layer of the M1. The measurements of signal intensity and cortical thickness for each subject were then averaged to obtain mean values from both cerebral hemispheres.

Quantitative data of cortical thickness and the signal intensity of the M1 were compared between patients and HS by using a Mann-Whitney U test. In the group of patients, the relationship between morphometric parameters (mean values of cortical thickness and signal intensity) and clinical scores (ALSFRS-R, Medical Research Council scale, disease duration, and DPR) and the electrophysiologic (central conduction time, cortical latency, cortical silent period) and laboratory (ferric reducing ability of plasma, advanced oxidation protein products, plasma thiols) data was evaluated by the Spearman rank correlation coefficient. Cortical thickness and signal intensity of the M1 for each Penfield’s area of hand, leg, and foot were correlated to the correspondent UMN score by using the Spearman rank correlation coefficient.

Using the median of DPR as a cutoff, we divided patients on the basis of the progression rate into 2 groups: “faster” and “slower.” A Mann-Whitney U test was applied to investigate differences in morphometric parameters between the 2 groups.

RESULTS

Four patients and 1 healthy control subject were excluded from the analysis due to the presence of severe motion artifacts.
In the remaining 18 patients, the mean values were 40 ± 5 for ALSFRS-R, 9 ± 10 for the UMN score, 118 ± 13 for the Medical Research Council scale, 16 ± 12 for disease duration, and 0.68 ± 0.47 for DPR.

**Visual Inspection and Subjective Assessment**

At visual inspection, reader 1 detected hypointensity and thinning of the deeper layers of the M1 in 12 of 18 patients with ALS and in 3 of 13 HS. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy in distinguishing patients and HS on the basis of morphologic criteria were 67%, 77%, 80%, 63%, and 71%, respectively.

Reader 2 detected hypointensity and thinning of the deeper layers of the M1 in 9 of 18 patients with ALS and in zero of 13 HS. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy in distinguishing patients and HS on the basis of morphologic criteria were 50%, 100%, 100%, 59%, and 71%, respectively.

The Interobserver agreement was good (0.61, Cohen κ statistic).

On the basis of both readings, the UMN score was significantly higher \((P = .003\) and \(P = .028\), respectively) in correctly diagnosed patients \((13 \pm 10 \text{ and } 14 \pm 10, \text{ respectively})\) than in misdiagnosed ones \((1 \pm 1 \text{ and } 4 \pm 8, \text{ respectively})\) (On-line Fig 1A, -B and On-line Tables 3–6).

Also, the DPR was higher on the basis of both readings \((P = .019\) and \(P = .066, \text{ respectively})\) in correctly diagnosed patients \((0.85 \pm 0.48 \text{ and } 0.87 \pm 0.49, \text{ respectively})\) than in misdiagnosed ones \((0.33 \pm 0.20 \text{ and } 0.48 \pm 0.38, \text{ respectively})\).

**Quantitative Assessment**

Cortical thickness was significantly \((P < .001)\) lower in patients (mean value = 1.5 mm) than in HS (mean value = 2 mm) (On-line Fig 1C) and showed a moderate correlation with the UMN score \((r = -0.59; P < .001)\) (Fig 2A). Cortical thickness had a weaker correlation with DPR \((r = -0.47; P = .051)\) and ALSFRS-R \((r = 0.49; P = .039)\) (Fig 2B, -C).

Signal intensity did not differ between patients with ALS and HS (On-line Fig 1D) but correlated with UMN score \((r = -0.47; P < .001), \text{ DPR} (r = -0.60; P = .009), \text{ and ALSFRS-R} (r = 0.45; P = .061)\) (Fig 2D–F).

Signal intensity in the subgroup of patients with faster DPR was significantly lower than that in the slower DPR subgroup \((P = .024)\), while no significant difference in cortical thickness was found between subgroups of patients (On-line Fig 2).

No significant correlations were found between morphometric parameters and either motor-evoked potential indices (central motor conduction time and cortical silent period) or the ferric-reducing ability of plasma, advanced oxidation protein products, and thiols.

**DISCUSSION**

**UHF MR Signal in M1 of Controls and Patients with ALS**

UHF MR imaging allows an in vivo evaluation of the inner structure of the cerebral motor cortex of patients with ALS and controls. The gradient recalled-echo T2* sequence at 7T provides information on the architectural organization of the human cortex in vivo, due to the iron and myelin contribution to T2* contrast. Because myelin and iron in the form of ferritin are strongly co-localized in the intracortical myelinated fibers, the MR signals across the cortical gray matter reflect myelin content and myeloarchitecture. The normal anatomy of the M1 (Brodmann area 4) at UHF depends on its peculiar architecture: The large cortical thickness, inconspicuous lamination pattern, low cell density, and the absence of a clear boundary between layer VI...
and white matter\textsuperscript{36} correspond to the MR imaging findings of the motor cortex as shown in Fig 1A, -B.

In patients with ALS, in accordance with previous ex vivo UHF images of the affected cerebral cortices,\textsuperscript{9} we revealed a rim of signal hypointensity with an inconsistent track appearance beneath a preserved superficial hyperintense cortical layer (Fig 1D, -E).

The decreased signal intensity of the motor cortex on T2*-weighted images in patients with ALS may represent ferritin because at postmortem examination, the precentral cortex showed intensely stained microglia and macrophages after antiferritin antibody staining.\textsuperscript{13} Until now, cortical hypointensity in vivo seemed to involve the motor cortex in a full-thickness fashion at both conventional\textsuperscript{37} and UHF\textsuperscript{9} MR imaging. Our targeted UHF MR imaging high-resolution study, as well as the ex vivo UHF imaging, demonstrated that in patients with ALS, the signal hypointensity is confined to the deeper layers of the cerebral cortex, the same structures in which several studies have shown an increased number of microglial cells resulting from local proliferation of resident microglia.\textsuperscript{38}

PET with radioligand-binding biomarkers of activated microglia revealed that areas with the highest microglial activation in patients with ALS were the motor cortices,\textsuperscript{39} thus corresponding to the distribution of signal changes and atrophy that we have detected in our group of patients.

**Cortical Thickness in the M1 of Patients with ALS**

Cortical atrophy in ALS has been revealed in several voxel-based morphometry works\textsuperscript{30,42} by manual or automated measurements of the cortical thickness and has been interpreted as a structural surrogate of UMN degeneration.\textsuperscript{23} In particular, the regional grade of atrophy in different areas of M1 corresponds to a somatotopic functional disability supporting the concepts of cortical focality and motor phenotype heterogeneity.\textsuperscript{44} In line with previous results, our data confirmed the thinning of the M1 in patients with ALS and the correlation between the cortical atrophy and the UMN burden, but we observed that the alteration is confined to the deeper cortical layers rather than the full-thickness cortex. Moreover, cortical atrophy and signal hypointensity of the M1 in patients with ALS are in line, respectively, with the reduction of N-acetylaspartate and the increase of myo-inositol\textsuperscript{44} as an expression of the neurodegenerative phenomena and gliosis.

**MR Imaging of M1: Biomarker for Diagnosis or Prognosis**

Several conventional MR imaging studies subjectively evaluated the cortical morphology and signal changes in patients with ALS.\textsuperscript{37,45-49} These studies using full-thickness measures of cortical signal changes were limited by low specificity because similar findings are age-related and can also be detected in subjects without ALS.\textsuperscript{50} Although our approach permitted the evaluation of the inner structure of the cerebral motor cortex, the diagnostic accuracy (71%) and the sensitivity (67% and 50% for reader 1 and reader 2, respectively) of M1 morphologic changes remain unsatisfactory.

Unlike electrophysiologic data, in which a correlation with UMN impairment has never been demonstrated,\textsuperscript{51} in our study, the quantitative analysis showed that increased image hypointensity and the atrophic deep motor cortex both correspond to greater UMN involvement. The correlation between the signal intensity and the UMN score and the fact that the UMN score was significantly higher in correctly diagnosed patients than in misdiagnosed ones support the hypothesis that hypointensity is a marker of UMN degeneration rather than of ALS.

This relationship influences the diagnostic accuracy of MR imaging, which remains modest because the correct diagnosis of ALS based on cortical signal changes depends on the amount of UMN impairment in sampled patients. The variable impairment of UMNs in ALS explains why decreased signal intensity in ALS has been reported at a variable extent, ranging from 93%\textsuperscript{37} to 30%.\textsuperscript{13}

The cortical signal intensity correlates with DPR and could constitute a prognostic marker of the disease. Although we interpret signal intensity as an expression of activated microglia, we do not know the pathologic mechanism that regulates the disease progression in our patients.

Translational research in mutant SOD1 transgenic mice shows that microglial cells become activated before motor neurons disappear and well before clinical disease onset.\textsuperscript{52} Moreover SOD mutant levels in microglia regulate the rate of disease progression.\textsuperscript{53} The correlation between cortical signal hypointensity as a presumptive marker of activated microglia and DPR could constitute the basis of a longitudinal study of microgliosis in patients with ALS, widening the pathogenic scenario of the causes of this disease and offering novel targets for therapeutic development. To understand whether the neuroinflammatory reaction could be a therapeutic target in ALS, a reliable biomarker able to investigate and monitor the neuroinflammatory response to motor-neuron degeneration with time would be desirable. Besides laboratory inflammatory markers in the CSF\textsuperscript{54} and PET studies by using microglial ligands, high-resolution UHF MR imaging might provide alternative relevant information on neuroinflammation.

In ALS, biomarkers of disease or prognosis would be paramount for patient management and therapeutic implications.\textsuperscript{5} Advanced neuroimaging techniques provide an opportunity to assess disease pathophysiology and promise new biomarkers.\textsuperscript{55} The introduction of the UHF MR imaging of the cerebral cortex in evaluating patients with ALS could be an adjunctive tool in a multimodal approach to the research of biomarkers.\textsuperscript{5}

The main limitation of the present study is the small sample of patients, which affects the statistical power. A further limitation is the impossibility of enrolling patients with advanced disease for logistic reasons related to their disability, which would probably have provided information on the course of the disease.

**CONCLUSIONS**

The combined high spatial resolution and sensitivity to paramagnetic substances of 7T MR imaging demonstrate in vivo signal changes of the cerebral motor cortex that resemble the distribution of activated microglia within the cortex of patients with ALS. Reduced cortical thickness and signal hypointensity of the M1 deep layers could constitute a marker of UMN impairment in patients with ALS. Further studies with a larger sample of patients would be desirable to confirm the UMN MR imaging results in motor neuron disorders.
References


52. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249–56 CrossRef Medline


57. Glasser MF, Van Essen DC. Mapping human cortical areas in vivo based on myelin content as revealed by T1- and T2-weighted MRI. J Neuroscience 2011;31:11597–616 CrossRef Medline
